The chronic hepatitis D virus market is expected to grow steadily, driven by a relatively small pipeline of emerging therapies. Leading candidates, such as Brelovitug from Bluejay Therapeutics and the ...

Nearly half of patients with chronic hepatitis D virus (HDV) infection treated with bulevirtide achieved the combined primary endpoint of reduced or undetectable HDV RNA levels and normalized alanine ...

This story is part of a larger series on viroids and virusoids, small infectious RNAs. It is also the eighth installment in a series on hepatitis D virus, a virusoid-like pathogen that causes serious ...

The World Health Organization (WHO) has reclassified Hepatitis D as carcinogenic to humans, placing it in the same league as Hepatitis B and C—both already known for causing liver cancer. According to ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Up to 57% of patients with chronic hepatitis D virus ...

The chronic hepatitis D market is expected to grow steadily through 2034, supported by a small but advancing pipeline targeting a long-standing unmet need, according to research from DelveInsight.

This story is part of a larger series on viroids and virusoids, small infectious RNAs. It is also the seventh installment in a series on hepatitis D virus, a virusoid-like pathogen that causes serious ...

Please provide your email address to receive an email when new articles are posted on . Patients with HIV and hepatitis B coinfection are at an increased risk for hepatitis D. Patients with hepatitis ...

Hepatitis D (also called Delta hepatitis) is a rare but a fatal type of Hepatitis, a deadly liver infection. This is caused by the Hepatitis D virus. Surprisingly, hepatitis D only affects people who ...

Huahui Health announced that China National Medical Products Administration (NMPA) has granted conditional approval to its ...

The chronic hepatitis D virus market is expected to grow steadily, driven by a relatively small pipeline of emerging therapies. Leading candidates, such as Brelovitug from Bluejay Therapeutics ...